appl inc hold pt iphon price strategi take advantag one year sens modul
remain uniqu rais pt analyst nehal chokshi full summari
atossa genet inc ato buy pt confer call discuss data topic endoxifen men
veru inc veru buy pt bridg xtandi/zytiga chemo ind phase
corpor event call maxim salesperson inform
scynexi inc scyx cover mccarthi ndr boston ceo marco taglietti cfo eric francoi thur sept
beigen ltd bgne cover mccarthi institut group dinner nyc cfo howard liang tue oct
domino pizza inc cover hq meet ann arbor ceo ritch allison cfo jeff
agilysi inc cover klee ndr nyc ceo ramesh srinivasan cfo toni pritchett thur sept
agilysi inc cover klee ndr boston ceo ramesh srinivasan cfo toni pritchett fri sept
cover klee confer call cso seth moor fri sept
net uep technolog inc uep cover klee ndr nyc cfo smith head india investor
net uep technolog inc uep cover klee ndr boston cfo smith head india
iphon price strategi take advantag one
year sens modul remain uniqu
iphon price strategi take advantag one year sens
modul remain uniqu rais iphon asp estim y/
declin y/i increas
rais estim pt accordingli reiter
iphon price strategi take advantag one year sens
modul remain uniqu rais iphon asp estim
y/i declin y/i increas septemb host
annual event unveil next gener iphon year row
price scheme consist effect price increas year price increas
justifi introduc sens technolog three lead headset well
elimin lowest asp sku iphon se start ad
new higher end asp sku iphon xs price scheme
expect previous assum android competit would success replic
sens technolog would result price pressur aapl premium
sku temper asp increas expect recognit last major asp
increas iphon cycl y/i due introduct
plu form factor follow y/i asp declin cycl believ
declin cycl result pent demand skew
toward less price sensit iphon user believ similar skew occur
iphon cycl given price point year ago price point see
figur comparison take account skew less price sensit
iphon user buy iphon cycl project iphon
increas y/i howev still expect android competit
catch within expect prompt respond price
cut begin next iphon line-up announc septemb
assum asp declin expect get push
rais estim pt accordingli reiter hold
rate increas iphon asp estim y/i
y/i maintain iphon unit estim y/i
reduc iphon unit estim expect effect asp increas
larg inelast absorb given on-going differenti face id bring
enabl sens modul y/i declin underpin
data suggest smartphon market declin mirror pc industri
result declin number new increment user
smartphon penetr rate near satur extend lifecycl
result increas asp estim without reduc iphon unit rais
iphon revenu estim y/i result
overal revenu estim increas y/i consensu
increas revenu estim also result increas ep
consist current consensu result
increas price target remain base
multipl ep estim plu net cash
click full note
pdufa date symjepi jr approach expect
posit respons fda symjepi partner
sandoz-novarti nv nr expect sandoz launch
symjepi product sometim second half follow low-dos approv
though precis time announc
admp share trade near low follow approv
teva teva hold gener epipen epipen jr though
view approv expect share steadili rise
pdufa approach approv launch
sandoz repres catalyst stock also await ex-u
strategi announc recal sandoz us
watch naloxone- nda file adami naloxon use
injector technolog symjepi also approach expect late
addit upsid see symjepi activ opioid space
around naloxon support view adami product yet
factor current valuat
naloxon manufactur adapt pharma up-front mileston
emerg note believ narcan gener
grow opioid epidem plenti room adami intramuscular
im administr may offer benefit intra-nas reduc
re-administr avail im injector market
kaleo privat evzio sell
symjepi first pipelin next adami inject inhalation-bas product
latter could particularli attract partner technolog differenti
use lower dose still induc effect avail option owe
small particl size inhal well featur devic tape etc
naloxon opioid od pend minor addit work nda
could file late review product could launch
sublingu tidalafil ciali ind file comparison studi
ciali potenti nda file earli year-end nr gener
ciali
inhal steroid asthma/copd fda clear studi
could begin patient recruit expect could see data
earli nda corticosteroid market includ
teva qvar
fluticason asthma poc studi first demonstr proper
dose steroid phase next expect potenti approval/launch
fluticason gener per year led flovent glaxosmithklin
gsk nr gener
fluticasone/salmeterol asthma combo therapi ideal
prioriti easier monotherapi get approv
first go combo product follow view
target advair market also gsk product
click full note
bridg xtandi/zytiga chemo
ind phase prostat cancer
veru announc compani complet success pre-ind meet
fda plan trial oral anti-tubulin metastat
prostat cancer ind submiss next studi initi
studi evalu pc patient fail
respond zytiga xtandi option patient iv
chemotherapi import note patient move one anti-
androgen next next option iv chemotherapi could
bridg anti-androgen iv chemo increas time patient
iv chemo necessari drop studi men
fail anti-androgen therapi signific catalyst veru
share view stir pc space compani expect initi safeti
efficaci data earli pend time studi start
expand opportun next-gener oral anti-
tubulin alpha beta oral chemo could serv bridg
anti-androgen therapi resist seen year taxan iv
chemotherapi veru initi evalu treatment mcrpc
approv xtandi nmcrpc follow approv erleada
signal us incorpor anti-androgen treatment paradigm
expand larger pc popul earlier diseas shift soc
default significantli increas opportun potenti bridg
therapi iv chemotherapi trial patient fail anti-
androgen xtandi zytiga expect initi data expect
primari endpoint reduct prostate-specif antigen
paradigm shift prostat cancer pc treatment anti-androgen
move earlier line pc therapi
prior high patient asymptomat treat cancer eventu break
castrat resist progress first metastasi treat anti-
androgen xtandi zytiga cancer break iv anti-tubulin chemo
high come first xtandi juli erleada
approv feb given high still asymptomat diseas
metastasi overal much larger popul move therapeut
pyramid shift standard care
translat anti-androgen use earlier even though time
diseas progress extend resist cancer breakthrough still like
occur challeng xtandi erleada zytiga use interchang
sequenti due cross-resist
read-through veru anti-androgen pre-metastasi set
first met patient experi exhaust anti-androgen
option earlier diseas significantli larger opportun
potenti bridg anti-androgen iv chemotherapi
forget patient live longer therapi hot
flash larger opportun well
click full note
confer call discuss data topic
endoxifen men
atossa announc compani host confer call thursday
discuss preliminari data subject studi topic
endoxifen men data posit posit compani
advanc topic trial men gynecomastia review
move studi gynecomastia would result compani
four on-going studi like data readout
oral endoxifen breast cancer on-going
topic endoxifen high densiti breast tissu mammograph
intraduct fulvestr breast cancer investig sponsor
topic endoxifen men gynecomastia could initi
earli
conclus recal endoxifen pathway given breadth
exist data efficaci safeti tamoxifen thu trial smaller
faster atossa continu see attract valuat market
capit potenti four trial report data
provid catalyst ato share
topic endoxifen phase subject support gynecomastia
gynecomastia condit character male breast enlarg occur
hormon imbal testosteron estrogen condit often
caus androgen depriv therapi prostat cancer affect
patient also caus anti-anxieti medic chemotherapi
heart medic embarrass often pain natur gynecomastia
lead complianc issu therapi caus condit common
affect men total radiat use
prophylact approv therapeut market select estrogen
receptor modul serm tamoxifen sometim use off-label topic
endoxifen develop men gynecomastia studi on-going
topic endoxifen dose clinic visit complet data
expect announc confer call support move
gynecomastia
endoxifen progress recal activ metabolit tamoxifen alreadi
establish safeti pk/pd efficaci reduc breast cancer recurr
risk profil atossa abl leverag exist pathway
develop endoxifen oral topic treatment result potenti smaller
faster clinic trial on-going upcom program includ
oral breast cancer studi complet demonstr endoxifen level well
therapeut threshold day vs day tamoxifen studi
open data
topic gynecomastia men studi complet data follow studi
topic high densiti breast women open
car-t deliveri intraduct car-t deliveri technolog still earli stage
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
